Profilin-2 (PFN2) (PFN2)

Profilin-2 (PFN2) is a 15 kDa actin-binding protein that serves as a key regulator of cytoskeletal dynamics, primarily by promoting the exchange of ADP for ATP on G-actin and facilitating its incorporation into filaments (UniProt P35080). While its isoform Profilin-1 is ubiquitously expressed, PFN2 is highly enriched in the central nervous system, where it modulates synaptic vesicle exocytosis and endocytosis through interactions with the SMN complex and various proline-rich proteins (NCBI Gene 5217). In oncology, PFN2 is frequently dysregulated; for instance, its overexpression in certain lung and gastric cancers promotes epithelial-mesenchymal transition (EMT), migration, and metastasis, making it a potential biomarker and therapeutic target (PubMed: 25650134). Conversely, in neurodegenerative contexts like Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA), PFN2's interaction with the Survival Motor Neuron (SMN) protein suggests a role in motor neuron stability and function (PubMed: 11804570). Although no clinical-grade drugs currently target PFN2, research into small molecules and antisense oligonucleotides is ongoing to modulate its activity in cancer and neurological disorders. Therapeutic challenges include the risk of systemic cytoskeletal disruption and the high degree of homology between profilin isoforms, which complicates the development of selective inhibitors.

Other names

PFN2PBE2Profilin II

None currently established for clinical drugs; research focuses on inhibition of actin-binding and poly-proline interaction sites.